Evidence map›Paper›PMID 41172992›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

Defined distribution and features of lymph node therapies enable recruitment and manipulation of antigen-specific T cell response.

Shannon J Tsai, Senta M Kapnick, Sean T Carey, Ryan A McIlvaine, Yuan Rui, Haleigh B Eppler, Shrey A Shah, Christopher J Bridgeman, Alexis A Yanes, Sheneil K Black and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Microparticles synthesized from itaconate polyesters enable metabolite delivery and elicit immunoregulatory outcomes.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shannon J TsaiFischell Department of Bioengineering, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA.
Senta M KapnickRobert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA; Department of Veterans Affairs, VA Maryland Health Care System, 10 North Greene Street, Baltimore, MD 21201, USA.
Sean T CareyFischell Department of Bioengineering, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA; Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA.
Ryan A McIlvaineFischell Department of Bioengineering, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA; Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA.
Yuan RuiFischell Department of Bioengineering, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA.
Haleigh B EpplerFischell Department of Bioengineering, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA.
Shrey A ShahFischell Department of Bioengineering, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA; Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA.
Christopher J BridgemanFischell Department of Bioengineering, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA; Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA.
Alexis A YanesFischell Department of Bioengineering, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA.
Sheneil K BlackFischell Department of Bioengineering, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA.
Xiangbin ZengFischell Department of Bioengineering, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA.
Joshua M GammonFischell Department of Bioengineering, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA.
Christopher M JewellRobert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, 8278 Paint Branch Drive, College Park, MD 20742, USA; Department of Veterans Affairs, VA Maryland Health Care System, 10 North Greene Street, Baltimore, MD 21201, USA; Marlene and Stewart Greenebaum Cancer Center, 22 South Greene Street, Suite N9E17, Baltimore, MD 21201, USA. Electronic address: cmjewell@umd.edu.

Funding

Defining the induction and maintenance of myelin-specific tolerance in T cells and B cells using local lymph node depotsR01AI169686 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI Christopher M Jewell · 2022 to 2026
$2.8M
Training in Host-pathogens interactionsT32AI089621 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI LEE, VINCENT T, MCIVER, KEVIN S. · 2010 to 2025
$2.1M
Improving multiple sclerosis patient quality of life using microneedle patches to simplify delivery of MS drugsR01AI144667 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI JEWELL, CHRISTOPHER M · 2019 to 2022
$1.6M
Harnessing biomaterials to study the link between local lymph node function and systemic toleranceR01EB026896 · NIBIB · UNIV OF MARYLAND, COLLEGE PARK · PI JEWELL, CHRISTOPHER M · 2018 to 2021
$1.5M
Identification of Legionella translocated effectorsF32AI069686 · NIAID · TUFTS UNIVERSITY BOSTON · PI HEIDTMAN, MATT · 2006 to 2008
$139k
Elucidating the role of APCs in immune tolerance during direct lymph node immunotherapyF31AI150198 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI EPPLER, HALEIGH · 2020 to 2021
$73k
BLRD VA IK2 BX005756NIAID NIH HHS F31 AI150198NIAID NIH HHS F32 AI069686NIAID NIH HHS R01 AI144667NIAID NIH HHS R01 AI169686NIAID NIH HHS T32 AI089621NIBIB NIH HHS R01 EB026896
6 · The paper itself

Abstract

Antigen-specific therapies to treat autoimmune diseases would benefit from improved understanding of the conditions needed to efficiently and selectively modulate inflammatory response. By leveraging the unique features of a spatially restricted platform to deliver polymer depots to lymph nodes (LNs), we establish design and delivery parameters required to locally regulate antigen-specific response. We show depots containing peptides and regulatory or stimulatory cues introduced directly to LNs recruit and engage antigen-specific T cells in treated LN microenvironments. This selectivity is maintained even during the administration of formulations containing multiple antigens, and the nature of this response can be switched between tolerizing or activating responses by defining cues in depots. Notably, in a myelin-driven model of autoimmunity, local depots promote re-polarization of inflammatory antigen-specific T cells into regulatory T cells. Efficacy against autoimmune disease is dose dependent but with low sensitivity to formulation parameters such as cargo-loading density and the ratio of antigen and modulatory cues in depots. This work defines cardinal features and delivery considerations for next-generation antigen-specific immunotherapies targeting autoimmune disease.

Indexed as

AntigensImmunotherapyLymph NodesT-LymphocytesAnimalsAutoimmunityDisease Models, AnimalHumansMiceMice, Inbred C57BLT-Lymphocytes, RegulatoryAntigensantigen-specific therapyautoimmunitybiomaterialsclinical manufacturing controlimmune engineeringlymph node therapiesmicroparticletarget product profiletolerance

Identifiers

PMID41172992
PMCPMC12685280

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.